NCT06440993 - Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 23, 2024

Primary Completion Date

January 31, 2027

Study Completion Date

April 30, 2028

Conditions

Extrahepatic CholangiocarcinomaUnresectable Perihilar or Ductal CCA

Interventions

DRUG

Gemcitabine

Gemcitabine, 1,000 mg/m2 IV

DRUG

Cisplatin

Cisplatin, 25 mg/m2 IV

DRUG

Durvalumab

Durvalumab, 1,500 mg IV

PROCEDURE

ID-RFA

endoscopic intraductal RFA

Trial Locations (3)

RECRUITING

Krankenhaus Nordwest, Frankfurt

NOT_YET_RECRUITING

Universitätsklinikum Köln, Cologne

RECRUITING

Universitätsklinikum Düsseldorf, Düsseldorf